Positives

• AOD-9604 may be interesting to a small subset of Long COVID or ME/CFS patients because it is marketed around fat metabolism, body composition, and recovery after illness-related deconditioning (PeptideEvidence).
• For most chronic illness patients, the more relevant question is not weight loss but whether metabolic or tissue-repair theories have any real symptom benefit (PubMed).

Negatives

• There is no good evidence that AOD-9604 improves brain fog, PEM, dysautonomia, MCAS, Lyme symptoms, or chronic fatigue (PeptideEvidence).
• The public discussion around it is heavily weight-loss and peptide-market oriented, which makes it easy to overstate relevance to post-viral illness (PeptideEvidence).

Hurdles & Side Effects

• AOD-9604 is not an approved Long COVID or ME/CFS treatment, and many products come from unregulated peptide sellers (PeptideEvidence).
• Patients would need to weigh uncertain benefit against cost, product-quality risk, and lack of long-term safety monitoring (PubMed).